Banque Cantonale Vaudoise Has $8.34 Million Stock Holdings in Stryker Corporation $SYK

Banque Cantonale Vaudoise boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 30.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 25,380 shares of the medical technology company’s stock after purchasing an additional 5,868 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Stryker were worth $8,340,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Apella Capital LLC boosted its position in shares of Stryker by 9.3% in the first quarter. Apella Capital LLC now owns 5,338 shares of the medical technology company’s stock valued at $1,833,000 after acquiring an additional 454 shares during the period. Godsey & Gibb Inc. increased its position in Stryker by 1.5% during the first quarter. Godsey & Gibb Inc. now owns 67,843 shares of the medical technology company’s stock worth $22,293,000 after acquiring an additional 1,012 shares during the period. Tranquility Partners LLC bought a new position in Stryker during the first quarter worth $311,000. Focused Wealth Management Inc raised its stake in Stryker by 37.7% during the 1st quarter. Focused Wealth Management Inc now owns 975 shares of the medical technology company’s stock valued at $320,000 after purchasing an additional 267 shares during the last quarter. Finally, Centennial Wealth Advisory LLC raised its stake in Stryker by 94.4% during the 1st quarter. Centennial Wealth Advisory LLC now owns 1,186 shares of the medical technology company’s stock valued at $390,000 after purchasing an additional 576 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Stryker Trading Up 1.2%

SYK stock opened at $313.87 on Thursday. The business has a fifty day moving average price of $311.87 and a 200 day moving average price of $340.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock has a market capitalization of $120.32 billion, a price-to-earnings ratio of 36.33, a P/E/G ratio of 1.99 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the prior year, the firm posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and set a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. Finally, Citigroup reduced their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.